TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $4.66 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.